Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303 Bartlett, Nancy L. , Wilson, Wyndham H. , Jung, Sin-Ho , Hsi, Eric D. ... - - J. Clin. Oncol - 2019 Manuscript - Primary - Primary - Lymphoma - CALGB-50303
Participation in cancer pharmacogenomic studies in 8,456 patients registered to Cancer and Leukemia Group B (Alliance) clinical trials Dressler, L. G. , Deal, A. M. , Watson, D. , Hollis, D. , Owzar, K. ... - - J. Clin. Oncol. - 2013 Abstract - Secondary-not-in-original - Meta-Analysis - Health Outcome - CALGB-40101 , CALGB-50303 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance) Dressler, Lynn G. , Deal, Allison M. , Owzar, Kouros ... - - J. Natl. Cancer Inst - 2015 Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcome - CALGB-40101 , CALGB-50303 , CALGB-80101 , CALGB-80203 , CALGB-80303 , CALGB-80405 , CALGB-90401
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial Schöder, Heiko , Polley, Mei-Yin C. , Knopp, Michael V. ... - - Blood - 2020 Manuscript - Secondary - Primary - Lymphoma - CALGB-50303
Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large B-cell lymphoma: Alliance/CALGB 50303 Wilson, Wyndham H. , Jung, Sin-Ho , Pitcher, Brandelyn , Hsi, Eric ... - ASH - Blood - 2016 Abstract - Primary - Primary - Lymphoma - CALGB-50303
